1 BTC
=
- USD
Viridian Therapeutics, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Viridian Therapeutics, Inc. Common Stock
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Market Statistics
Trading Metrics
How to Buy VRDN
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy VRDN
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesHighVista Strategies sold 238,243 shares of Viridian Therapeutics (worth ~$7.08 million) in Q1 2026, reducing its position by $8.97 million when accounting for stock price movements. The sale may reflect profit-taking ahead of the company's June 30 FDA decision on its lead therapy veligrotug. Despite recent stock volatility following Phase 3 data that beat expectations, Viridian remains positioned as a potential commercial player in the thyroid eye disease market with its subcutaneous candidate elegrobart.
Kopp Family Office reduced its Viridian Therapeutics stake by 117,878 shares ($3.5M) in Q1 2026, cutting the position from 3.4% to 0.7% of AUM. The move appears prescient as Viridian shares have fallen 50% since mid-March following disappointing Phase 3 data for elegrobart and stronger competing results from Amgen's Tepezza variant, raising questions about market differentiation for the clinical-stage biotech.
Johnson Fistel, PLLC is investigating potential securities fraud claims on behalf of investors in J.Jill, RH, and Viridian Therapeutics. The J.Jill investigation was prompted by the company's March 31, 2026 earnings disclosure revealing poor holiday assortment performance, increased competitive promotions, and customer migration toward discounted pricing, raising questions about compliance with federal securities laws.
Johnson Fistel, PLLP announced investigations into potential securities law violations by Viridian Therapeutics, Braskem S.A., and TAT Technologies Ltd. on behalf of investors who suffered losses. The investigation into Viridian focuses on whether the company complied with federal securities laws following its announcement of Phase 3 clinical trial results for its REVEAL-1 trial.
Commodore Capital completely exited its 3.2 million share position in Viridian Therapeutics (worth $69 million) on February 17, 2026, reducing the holding from 3.4% of the fund's assets to zero. This comes despite Viridian's stock being up 75% over the past year and entering a catalyst-heavy 2026 with FDA approval decisions and Phase 3 data expected. The exit suggests the fund may be taking profits after the strong rally or reallocating capital to other clinical-stage biotech names.
